Clinical Trial Calendar

Results Date
Company Name
Mid 2021
Top-line results from pivotal phase II study of Resminostat
Cutaneous T cell lymphoma
Mid 2021
Alnylam Pharmaceuticals Inc.
Initial results from phase III study of Lumasiran (ILLUMINATE-C )
Advanced Primary Hyperoxaluria Type 1
Mid 2021
Clearside Biomedical, Inc.
Initial safety data from the first cohort of phase I/IIa clinical trial of CLS-AX
Neovascular age-related macular degeneration (wet AMD)
Mid 2021
Jaguar Health, Inc.
Results from pilot study of Mytesi
Chronic Idiopathic Diarrhea in adult non-HIV patients
Mid 2021
Jaguar Health, Inc.
Final results from phase II study of Mytesi(HALT-D)
Diarrhea in HER2-positive Breast Cancer Patients
Mid 2021
Arcutis Biotherapeutics Inc.
Topline data from Phase 2b portion of Phase 1/2b study of ARQ-252
Chronic hand eczema
Mid 2021
Evelo Biosciences, Inc.
Interim data from Phase 2 trial of EDP1815
Moderate psoriasis
Mid 2021
Evelo Biosciences, Inc.
Data from Phase 1b trial of EDP1867
Atopic dermatitis
Mid 2021
Marinus Pharmaceuticals
Submission of NDA for oral Ganaxolone
CDKL5 deficiency disorder (CDD)
Mid 2021
Checkpoint Therapeutics, Inc.
Full top-line results from Registration-Enabling Trial of Cosibelimab
Metastatic Cutaneous Squamous Cell Carcinoma
Mid 2021
Synlogic Inc
Data from phase II clinical trial of SYNB1618
Mid 2021
Aeglea BioTherapeutics, Inc.
Topline data from pivotal Phase III trial of Pegzilarginase (PEACE)
Arginase 1 Deficiency
Mid 2021
argenx SE
Data from Phase 1 study of IV and SC ARGX-117 targeting complement C2
Healthy volunteer
Mid 2021
AVEO Pharmaceuticals, Inc.
Results from Phase 2 study of Ficlatuzumab in combination with cetuximab
Metastatic head and neck squamous cell cancer (HNSCC)
Q2 2021
Aileron Therapeutics, Inc.
Data Readout from Phase 1b Clinical Trial of ALRN-6924
Healthy Volunteer Study
Q2 2021
Kintara Therapeutics, Inc
Topline results from Phase 2 Study of VAL-083
MGMT Unmethylated Bevacizumab-naïve Glioblastoma in the Adjuvant or Recurrent Setting
Q2 2021
Tonix Pharmaceuticals Holding Corp.
Interim results from phase III trial of TNX-102 SL (RALLY)
Q2 2021
Fulcrum Therapeutics
Full data from phase II clinical trial of Losmapimod to include analyses of DUX4 gene signature and MRI(ReDUX4)
Facioscapulohumeral muscular dystrophy
Q2 2021
Enanta Pharmaceuticals Inc.
Preliminary data from Phase 1b study of core Inhibitor EDP-514
NUC-suppressed Hepatitis B (HBV) patients
Q2 2021
Enanta Pharmaceuticals Inc.
Data from phase 1 study of EDP-297
Non-Alcoholic Steatohepatitis (NASH)
Q2 2021
Entera Bio Ltd.
Final Biomarker Data from 2.5 mg Dose in Phase 2 Study of EB613
Q2 2021
Corbus Pharmaceuticals Holdings, Inc.
Topline data from Phase 3 study of Lenabasum (DETERMINE)
Dermatomyositis (DM)
Q2 2021
Novan Inc.
Top-line efficacy results from phase 3 trial of SB206 (B-SIMPLE4)
Q2 2021
AzurRx BioPharma, Inc.
Topline data from phase 2 combination therapy trial of MS1819 with PERT therapy
Cystic fibrosis (CF) and chronic pancreatitis (CP) patients with exocrine pancreatic insufficiency (EPI)
Q2 2021
Celldex Therapeutics Inc.
Full results from Phase 1b study of CDX-0159
Chronic spontaneous urticaria (CSU)